BR112021011143A2 - Composições para redução específica de drg da expressão de transgene - Google Patents
Composições para redução específica de drg da expressão de transgeneInfo
- Publication number
- BR112021011143A2 BR112021011143A2 BR112021011143A BR112021011143A BR112021011143A2 BR 112021011143 A2 BR112021011143 A2 BR 112021011143A2 BR 112021011143 A BR112021011143 A BR 112021011143A BR 112021011143 A BR112021011143 A BR 112021011143A BR 112021011143 A2 BR112021011143 A2 BR 112021011143A2
- Authority
- BR
- Brazil
- Prior art keywords
- drg
- expression
- cells
- compositions
- aav
- Prior art date
Links
- 108700019146 Transgenes Proteins 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title abstract 2
- 210000000234 capsid Anatomy 0.000 abstract 1
- 239000012537 formulation buffer Substances 0.000 abstract 1
- 238000001415 gene therapy Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 108091070501 miRNA Proteins 0.000 abstract 1
- 239000002679 microRNA Substances 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 210000003594 spinal ganglia Anatomy 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
- A61K35/761—Adenovirus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
- A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
- C12N2310/141—MicroRNAs, miRNAs
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Virology (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- General Chemical & Material Sciences (AREA)
- Mycology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
composições para redução específica de drg da expressão de transgene. a presente invenção refere-se a um aav recombinante (ra-av) compreendendo um capsídeo de aav e um genoma de vetor empacotado nele, em que o genoma do vetor compreende uma repetição terminal invertida (itr) 5' de aav, uma sequência de ácido nucleico modificada que codifica um produto genético para expressão em células-alvo e sequências-alvo de mirna que reprimem seletivamente a expressão em células do gânglio da raiz dorsal (drg). também é fornecida uma composição farmacêutica compreendendo um raav como descrito aqui em um tampão de formulação e um método de tratamento de um sujeito humano com terapia genética direcionada a cns, enquanto evita seletivamente a expressão em células drg.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862783956P | 2018-12-21 | 2018-12-21 | |
| US201962924970P | 2019-10-23 | 2019-10-23 | |
| US201962934915P | 2019-11-13 | 2019-11-13 | |
| PCT/US2019/067872 WO2020132455A1 (en) | 2018-12-21 | 2019-12-20 | Compositions for drg-specific reduction of transgene expression |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112021011143A2 true BR112021011143A2 (pt) | 2022-01-25 |
Family
ID=71100588
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112021011143A BR112021011143A2 (pt) | 2018-12-21 | 2019-12-20 | Composições para redução específica de drg da expressão de transgene |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US20210077553A1 (pt) |
| EP (1) | EP3908326A4 (pt) |
| JP (1) | JP7660062B2 (pt) |
| KR (1) | KR20210107037A (pt) |
| CN (1) | CN113646005A (pt) |
| AU (1) | AU2019401314A1 (pt) |
| BR (1) | BR112021011143A2 (pt) |
| CA (1) | CA3123600A1 (pt) |
| CL (1) | CL2021001624A1 (pt) |
| CO (1) | CO2021008538A2 (pt) |
| IL (1) | IL284185B2 (pt) |
| JO (1) | JOP20210160A1 (pt) |
| MX (1) | MX2021007600A (pt) |
| PE (1) | PE20211581A1 (pt) |
| PH (1) | PH12021551341A1 (pt) |
| SG (1) | SG11202105907QA (pt) |
| WO (1) | WO2020132455A1 (pt) |
Families Citing this family (58)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112021021908A2 (pt) | 2019-05-03 | 2022-02-01 | Univ Pennsylvania | Composições úteis no tratamento da leucodistrofia metacromática |
| AU2021257848A1 (en) | 2020-04-15 | 2022-12-01 | Voyager Therapeutics, Inc. | Tau binding compounds |
| WO2021231579A1 (en) * | 2020-05-12 | 2021-11-18 | The Trustees Of The University Of Pennsylvania | Compositions for drg-specific reduction of transgene expression |
| JP2023525810A (ja) | 2020-05-13 | 2023-06-19 | ボイジャー セラピューティクス インコーポレイテッド | Ａａｖカプシドの指向性の再指示 |
| WO2021247995A2 (en) | 2020-06-04 | 2021-12-09 | Voyager Therapeutics, Inc. | Compositions and methods of treating neuropathic pain |
| MX2022016528A (es) | 2020-06-17 | 2023-06-02 | Univ Pennsylvania | Composiciones y métodos para el tratamiento de pacientes de terapia génica. |
| IL299762A (en) | 2020-07-13 | 2023-03-01 | Univ Pennsylvania | Useful preparations for the treatment of Charcot-Marietot disease |
| US20230285596A1 (en) | 2020-07-27 | 2023-09-14 | Voyager Therapeutics, Inc | Compositions and methods for the treatment of niemann-pick type c1 disease |
| AU2021315876A1 (en) | 2020-07-27 | 2023-02-23 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of neurological disorders related to glucosylceramidase beta deficiency |
| AU2021359874A1 (en) | 2020-10-18 | 2023-05-25 | The Trustees Of The University Of Pennsylvania | Improved adeno-associated virus (aav) vector and uses therefor |
| WO2022094078A1 (en) | 2020-10-28 | 2022-05-05 | The Trustees Of The University Of Pennsylvania | Compositions useful in treatment of rett syndrome |
| AU2021392642A1 (en) | 2020-12-01 | 2023-06-22 | The Trustees Of The University Of Pennsylvania | Compositions and uses thereof for treatment of angelman syndrome |
| US20240141378A1 (en) | 2021-03-03 | 2024-05-02 | Voyager Therapeutics, Inc. | Controlled expression of viral proteins |
| US20240175050A1 (en) * | 2021-03-19 | 2024-05-30 | Mayo Foundation For Medical Education And Research | Methods and materials for treating propionic acidemia |
| WO2023113806A1 (en) | 2021-12-16 | 2023-06-22 | Affinia Therapeutics, Inc. | Recombinant aav for treatment of neural disease |
| WO2022221193A1 (en) | 2021-04-12 | 2022-10-20 | Affinia Therapeutics Inc. | Recombinant aav for treatment of neural disease |
| MX2023012513A (es) | 2021-04-23 | 2023-12-15 | Univ Pennsylvania | Nuevas composiciones con motivos selectivos para el cerebro y composiciones que las contienen. |
| TW202309066A (zh) | 2021-04-27 | 2023-03-01 | 賓州大學委員會 | 衍生自豬的腺相關病毒衣殼及其用途 |
| WO2023044483A2 (en) | 2021-09-20 | 2023-03-23 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of her2 positive cancer |
| EP4409010A1 (en) | 2021-10-02 | 2024-08-07 | The Trustees of The University of Pennsylvania | Novel aav capsids and compositions containing same |
| MX2024004723A (es) * | 2021-10-18 | 2024-07-19 | Univ Pennsylvania | Composiciones útiles en el tratamiento del trastorno por deficiencia de cdkl5 (cdd). |
| WO2023087019A2 (en) * | 2021-11-15 | 2023-05-19 | The Trustees Of The University Of Pennsylvania | Compositions for drg-specific reduction of transgene expression |
| WO2023092004A1 (en) | 2021-11-17 | 2023-05-25 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of tau-related disorders |
| EP4433490A2 (en) | 2021-11-17 | 2024-09-25 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of neurological disorders related to glucosylceramidase beta deficiency |
| EP4433169A1 (en) | 2021-11-17 | 2024-09-25 | Voyager Therapeutics, Inc. | Aav capsid variants and uses thereof |
| TW202340467A (zh) | 2022-01-10 | 2023-10-16 | 賓州大學委員會 | 有用於治療c9orf72介導之病症之組成物及方法 |
| EP4469585A2 (en) | 2022-01-25 | 2024-12-04 | Voyager Therapeutics, Inc. | Baculovirus expression system |
| KR20240161976A (ko) | 2022-02-08 | 2024-11-13 | 보이저 테라퓨틱스, 인크. | Aav 캡시드 변이체 및 이의 용도 |
| WO2023196892A1 (en) | 2022-04-06 | 2023-10-12 | The Trustees Of The University Of Pennsylvania | Passive immunization with anti- aav neutralizing antibodies to prevent off-target transduction of intrathecally delivered aav vectors |
| JP2025512969A (ja) | 2022-04-06 | 2025-04-22 | ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア | Ｈｅｒ２陽性転移性乳がん及び他のがんを治療するための組成物及び方法 |
| WO2023220695A2 (en) | 2022-05-13 | 2023-11-16 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of her2 positive cancer |
| KR20250025387A (ko) | 2022-06-02 | 2025-02-21 | 보이저 테라퓨틱스, 인크. | Aav 캡시드 변이체 및 이의 용도 |
| WO2023240236A1 (en) | 2022-06-10 | 2023-12-14 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of spinal muscular atrophy related disorders |
| WO2023250388A1 (en) | 2022-06-22 | 2023-12-28 | Voyager Therapeutics, Inc. | Tau binding compounds |
| TW202417467A (zh) | 2022-06-28 | 2024-05-01 | 美商航海家醫療公司 | Ａａｖ蛋白殼變異體及其用途 |
| TW202424201A (zh) | 2022-07-06 | 2024-06-16 | 美商航海家醫療公司 | Ａａｖ殼體變異體及其用途 |
| AU2023304708A1 (en) * | 2022-07-08 | 2025-01-23 | Consiglio Nazionale Delle Ricerche | Transgene cassettes |
| EP4565597A2 (en) | 2022-08-03 | 2025-06-11 | Voyager Therapeutics, Inc. | Compositions and methods for crossing the blood brain barrier |
| WO2024059739A1 (en) | 2022-09-15 | 2024-03-21 | Voyager Therapeutics, Inc. | Tau binding compounds |
| AU2023351041A1 (en) * | 2022-09-26 | 2025-03-13 | Encoded Therapeutics, Inc. | Elements for de-targeting gene expression in dorsal root ganglion and/or liver |
| TW202440939A (zh) | 2022-12-17 | 2024-10-16 | 賓州大學委員會 | 具心臟及骨骼肌特異性靶向模體的重組aav突變載體及含有其之組成物 |
| WO2024130070A2 (en) | 2022-12-17 | 2024-06-20 | The Trustees Of The University Of Pennsylvania | Recombinant aav capsids with cardiac- and skeletal muscle- specific targeting motifs and uses thereof |
| AU2023417630A1 (en) | 2022-12-29 | 2025-05-15 | Voyager Therapeutics, Inc. | Compositions and methods for regulating mapt |
| WO2024163012A1 (en) | 2023-02-02 | 2024-08-08 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of neurological disorders related to glucosylceramidase beta deficiency |
| WO2024226761A2 (en) | 2023-04-26 | 2024-10-31 | Voyager Therapeutics, Inc. | Compositions and methods for treating amyotrophic lateral sclerosis |
| TW202446960A (zh) | 2023-05-02 | 2024-12-01 | 美商航海家醫療公司 | 用於調控ｍａｐｔ之組合物及方法 |
| WO2024229161A1 (en) | 2023-05-03 | 2024-11-07 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of disorders related to glucosylceramidase beta 1 deficiency |
| WO2024229389A1 (en) | 2023-05-03 | 2024-11-07 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of tau-related disorders |
| TW202444917A (zh) | 2023-05-04 | 2024-11-16 | 美商航海家醫療公司 | Ａａｖ衣殼變異體及其用途 |
| WO2024235159A1 (zh) * | 2023-05-12 | 2024-11-21 | 上海金珂博生物技术有限公司 | 一种携带smn基因表达框的病毒载体及其用途 |
| TW202516019A (zh) | 2023-06-29 | 2025-04-16 | 賓州大學委員會 | 具中樞神經系統靶向模體的突變aav及含有其之組成物 |
| WO2025035143A1 (en) | 2023-08-10 | 2025-02-13 | The Trustees Of The University Of Pennsylvania | Compositions and methods for treatment of spinal muscular atrophy |
| WO2025038805A1 (en) | 2023-08-16 | 2025-02-20 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of disorders related to glucosylceramidase beta 1 deficiency |
| WO2025106661A1 (en) | 2023-11-14 | 2025-05-22 | The Trustees Of The University Of Pennsylvania | Compositions with cardiac and skeletal musclespecific targeting motifs and uses thereof |
| WO2025122530A1 (en) | 2023-12-05 | 2025-06-12 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of disorders related to glucosylceramidase beta 1 deficiency |
| WO2025122634A1 (en) | 2023-12-05 | 2025-06-12 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of tau-related disorders |
| WO2025122644A1 (en) | 2023-12-05 | 2025-06-12 | Voyager Therapeutics, Inc. | Compositions and methods for regulating mapt |
| WO2025129157A1 (en) | 2023-12-15 | 2025-06-19 | The Trustees Of The University Of Pennsylvania | Gene therapy for treatment of canavan disease |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1838870A2 (en) * | 2004-12-29 | 2007-10-03 | Exiqon A/S | NOVEL OLIGONUCLEOTIDE COMPOSITIONS AND PROBE SEQUENCES USEFUL FOR DETECTION AND ANALYSIS OF MICRORNAS AND THEIR TARGET MRNAs |
| CN101287834B (zh) * | 2005-05-27 | 2016-11-09 | 圣拉法埃莱医院有限公司 | 基因载体 |
| EP1966390A1 (en) * | 2005-12-29 | 2008-09-10 | Exiqon A/S | Detection of tissue origin of cancer |
| KR101026502B1 (ko) * | 2007-11-23 | 2011-04-01 | 주식회사 파나진 | 마이크로ｒｎａ 안티센스 ｐｎａ, 그를 포함하는 조성물, 및 그의 사용 및 평가 방법 |
| US9217155B2 (en) * | 2008-05-28 | 2015-12-22 | University Of Massachusetts | Isolation of novel AAV'S and uses thereof |
| ES2698203T3 (es) * | 2010-04-23 | 2019-02-01 | Univ Massachusetts | Vectores de AAV que se dirigen al SNC y métodos de uso de los mismos |
| FR3004463A1 (fr) | 2013-04-11 | 2014-10-17 | Genethon | Systeme d'expression pour une therapie genique selective |
| MA43968A (fr) * | 2016-02-03 | 2018-12-12 | Univ Pennsylvania | Thérapie génique pour traiter la mucopolysaccharidose de type i |
| JOP20190200A1 (ar) * | 2017-02-28 | 2019-08-27 | Univ Pennsylvania | تركيبات نافعة في معالجة ضمور العضل النخاعي |
-
2019
- 2019-12-20 JP JP2021535718A patent/JP7660062B2/ja active Active
- 2019-12-20 PE PE2021000908A patent/PE20211581A1/es unknown
- 2019-12-20 WO PCT/US2019/067872 patent/WO2020132455A1/en active Application Filing
- 2019-12-20 BR BR112021011143A patent/BR112021011143A2/pt unknown
- 2019-12-20 MX MX2021007600A patent/MX2021007600A/es unknown
- 2019-12-20 IL IL284185A patent/IL284185B2/en unknown
- 2019-12-20 EP EP19897715.9A patent/EP3908326A4/en active Pending
- 2019-12-20 CN CN201980092720.6A patent/CN113646005A/zh active Pending
- 2019-12-20 CA CA3123600A patent/CA3123600A1/en active Pending
- 2019-12-20 JO JOP/2021/0160A patent/JOP20210160A1/ar unknown
- 2019-12-20 KR KR1020217021804A patent/KR20210107037A/ko active Pending
- 2019-12-20 SG SG11202105907QA patent/SG11202105907QA/en unknown
- 2019-12-20 AU AU2019401314A patent/AU2019401314A1/en active Pending
-
2020
- 2020-11-13 US US17/097,997 patent/US20210077553A1/en active Pending
-
2021
- 2021-06-07 PH PH12021551341A patent/PH12021551341A1/en unknown
- 2021-06-17 CL CL2021001624A patent/CL2021001624A1/es unknown
- 2021-06-29 CO CONC2021/0008538A patent/CO2021008538A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL284185B2 (en) | 2025-04-01 |
| EP3908326A1 (en) | 2021-11-17 |
| US20210077553A1 (en) | 2021-03-18 |
| PE20211581A1 (es) | 2021-08-17 |
| JP7660062B2 (ja) | 2025-04-10 |
| CL2021001624A1 (es) | 2021-11-26 |
| IL284185B1 (en) | 2024-12-01 |
| MX2021007600A (es) | 2021-08-11 |
| EP3908326A4 (en) | 2022-10-26 |
| KR20210107037A (ko) | 2021-08-31 |
| CO2021008538A2 (es) | 2021-07-19 |
| CN113646005A (zh) | 2021-11-12 |
| CA3123600A1 (en) | 2020-06-25 |
| JOP20210160A1 (ar) | 2023-01-30 |
| IL284185A (en) | 2021-08-31 |
| AU2019401314A1 (en) | 2021-06-24 |
| JP2022517174A (ja) | 2022-03-07 |
| WO2020132455A1 (en) | 2020-06-25 |
| PH12021551341A1 (en) | 2021-12-13 |
| SG11202105907QA (en) | 2021-07-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112021011143A2 (pt) | Composições para redução específica de drg da expressão de transgene | |
| CL2020001428A1 (es) | Terapia genética para la mucopolisacaridosis iiib. | |
| MX2022014258A (es) | Composiciones para la reducción específica de un fármaco de la expresión de transgén. | |
| BR112014025985A2 (pt) | composição e métodos para transferência de gene altamente eficaz com o uso de variantes de capsídeo de aav | |
| RU2016105965A (ru) | Вариант aav, композиции и способы, в которых он используется, а также способы его применения для переноса генов в клетки, органы и ткани | |
| BR112019023303A2 (pt) | Terapia de gene para lipofuscinoses ceroides neuronais | |
| AR118850A1 (es) | Composiciones útiles en el tratamiento de leucodistrofia metacromática | |
| WO2019108857A8 (en) | Gene therapy for mucopolysaccharidosis iiia | |
| FI3313991T3 (fi) | Muunnettu tekijä IX sekä koostumukset, menetelmät ja käytöt geeninsiirtoa varten soluihin, elimiin ja kudoksiin | |
| BR112016028023A2 (pt) | Composições e métodos de administração de tratamentos para infecções virais latentes | |
| MX2020001402A (es) | Metodos de terapia genica del factor viii (fviii). | |
| BR112022019304A2 (pt) | Variantes de capsídeo de aav e usos das mesmas | |
| CO2023009633A2 (es) | Efecto sinérgico de smn1 y mir-23a en el tratamiento de la atrofia muscular espinal | |
| MX2023012509A (es) | Vectores aavrh74 para la terapia génica de distrofias musculares. | |
| MY204271A (en) | Viral vectors comprising rdh12 coding regions and methods of treating retinal dystrophies | |
| CL2023001650A1 (es) | Tratamiento de la enfermedad de danon | |
| MX2022011777A (es) | Itrs libres de cpg para la terapia genica aav. | |
| BR112021016566A2 (pt) | Composições úteis no tratamento da doença de krabbe | |
| EA202191744A1 (ru) | Композиции для drg-специфического снижения экспрессии трансгена | |
| WO2024011203A3 (en) | Ocular vectors and uses thereof | |
| CN111100847A (zh) | 安全性更高的端粒基因治疗产品使人体健康逆转衰老 | |
| BR112023015303A2 (pt) | Método para tratar doença cln2 devido a deficiência de tpp1 em um sujeito | |
| BR112022021786A2 (pt) | Composições úteis em tratamento de doença de krabbe | |
| CO2025004844A2 (es) | Vectores de aav recombinantes para tratamiento de distrofia muscular | |
| MX2018011744A (es) | Metodos y composiciones para el tratamiento de esclerosis lateral amiotrofica. |